139 related articles for article (PubMed ID: 11751017)
21. Pharmacokinetics and biodistribution studies of Doxorubicin loaded poly(butyl cyanoacrylate) nanoparticles synthesized by two different techniques.
Reddy LH; Murthy RS
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2004 Dec; 148(2):161-6. PubMed ID: 15744366
[TBL] [Abstract][Full Text] [Related]
22. Intranasal delivery of cancer-targeting doxorubicin-loaded PLGA nanoparticles arrests glioblastoma growth.
Chung K; Ullah I; Kim N; Lim J; Shin J; Lee SC; Jeon S; Kim SH; Kumar P; Lee SK
J Drug Target; 2020 Jul; 28(6):617-626. PubMed ID: 31852284
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of Cisplatin-loaded polybutyl cyanoacrylate nanoparticles on the glioblastoma.
Ebrahimi Shahmabadi H; Movahedi F; Koohi Moftakhari Esfahani M; Alavi SE; Eslamifar A; Mohammadi Anaraki G; Akbarzadeh A
Tumour Biol; 2014 May; 35(5):4799-806. PubMed ID: 24443270
[TBL] [Abstract][Full Text] [Related]
24. Indirect evidence that drug brain targeting using polysorbate 80-coated polybutylcyanoacrylate nanoparticles is related to toxicity.
Olivier JC; Fenart L; Chauvet R; Pariat C; Cecchelli R; Couet W
Pharm Res; 1999 Dec; 16(12):1836-42. PubMed ID: 10644071
[TBL] [Abstract][Full Text] [Related]
25. Reversion of multidrug resistance by co-encapsulation of doxorubicin and curcumin in chitosan/poly(butyl cyanoacrylate) nanoparticles.
Duan J; Mansour HM; Zhang Y; Deng X; Chen Y; Wang J; Pan Y; Zhao J
Int J Pharm; 2012 Apr; 426(1-2):193-201. PubMed ID: 22274587
[TBL] [Abstract][Full Text] [Related]
26. Targeted delivery of tacrine into the brain with polysorbate 80-coated poly(n-butylcyanoacrylate) nanoparticles.
Wilson B; Samanta MK; Santhi K; Kumar KP; Paramakrishnan N; Suresh B
Eur J Pharm Biopharm; 2008 Sep; 70(1):75-84. PubMed ID: 18472255
[TBL] [Abstract][Full Text] [Related]
27. Direct evidence that polysorbate-80-coated poly(butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drug to the nanoparticles.
Kreuter J; Ramge P; Petrov V; Hamm S; Gelperina SE; Engelhardt B; Alyautdin R; von Briesen H; Begley DJ
Pharm Res; 2003 Mar; 20(3):409-16. PubMed ID: 12669961
[TBL] [Abstract][Full Text] [Related]
28. A Comparative Study of Orally Delivered PBCA and ApoE Coupled BSA Nanoparticles for Brain Targeting of Sumatriptan Succinate in Therapeutic Management of Migraine.
Girotra P; Singh SK
Pharm Res; 2016 Jul; 33(7):1682-95. PubMed ID: 27003706
[TBL] [Abstract][Full Text] [Related]
29. 'Dendrimer-Cationized-Albumin' encrusted polymeric nanoparticle improves BBB penetration and anticancer activity of doxorubicin.
Muniswamy VJ; Raval N; Gondaliya P; Tambe V; Kalia K; Tekade RK
Int J Pharm; 2019 Jan; 555():77-99. PubMed ID: 30448308
[TBL] [Abstract][Full Text] [Related]
30. Intracellular drug delivery using polysorbate 80-modified poly(D,L-lactide-co-glycolide) nanospheres to glioblastoma cells.
Tahara K; Kato Y; Yamamoto H; Kreuter J; Kawashima Y
J Microencapsul; 2011; 28(1):29-36. PubMed ID: 21171814
[TBL] [Abstract][Full Text] [Related]
31. A multifunctional polymeric nanotheranostic system delivers doxorubicin and imaging agents across the blood-brain barrier targeting brain metastases of breast cancer.
Li J; Cai P; Shalviri A; Henderson JT; He C; Foltz WD; Prasad P; Brodersen PM; Chen Y; DaCosta R; Rauth AM; Wu XY
ACS Nano; 2014 Oct; 8(10):9925-40. PubMed ID: 25307677
[TBL] [Abstract][Full Text] [Related]
32. Liposome-mediated therapy of intracranial brain tumors in a rat model.
Sharma US; Sharma A; Chau RI; Straubinger RM
Pharm Res; 1997 Aug; 14(8):992-8. PubMed ID: 9279878
[TBL] [Abstract][Full Text] [Related]
33. Solid lipid nanoparticles for potential doxorubicin delivery in glioblastoma treatment: preliminary in vitro studies.
Battaglia L; Gallarate M; Peira E; Chirio D; Muntoni E; Biasibetti E; Capucchio MT; Valazza A; Panciani PP; Lanotte M; Schiffer D; Annovazzi L; Caldera V; Mellai M; Riganti C
J Pharm Sci; 2014 Jul; 103(7):2157-2165. PubMed ID: 24824141
[TBL] [Abstract][Full Text] [Related]
34. Effects of apolipoproteins on dalargin transport across the blood-brain barrier.
Shamenkov DA; Petrov VE; Alyautdin RN
Bull Exp Biol Med; 2006 Dec; 142(6):703-6. PubMed ID: 17603675
[TBL] [Abstract][Full Text] [Related]
35. Pronounced antitumor efficacy of doxorubicin when given as the prodrug DOX-GA3 in combination with a monoclonal antibody beta-glucuronidase conjugate.
Houba PH; Boven E; van der Meulen-Muileman IH; Leenders RG; Scheeren JW; Pinedo HM; Haisma HJ
Int J Cancer; 2001 Feb; 91(4):550-4. PubMed ID: 11251980
[TBL] [Abstract][Full Text] [Related]
36. Doxorubicin encapsulated in sterically stabilized liposomes for the treatment of a brain tumor model: biodistribution and therapeutic efficacy.
Siegal T; Horowitz A; Gabizon A
J Neurosurg; 1995 Dec; 83(6):1029-37. PubMed ID: 7490617
[TBL] [Abstract][Full Text] [Related]
37. Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer's disease.
Wilson B; Samanta MK; Santhi K; Kumar KP; Paramakrishnan N; Suresh B
Brain Res; 2008 Mar; 1200():159-68. PubMed ID: 18291351
[TBL] [Abstract][Full Text] [Related]
38. Nanoparticulate systems for brain delivery of drugs.
Kreuter J
Adv Drug Deliv Rev; 2001 Mar; 47(1):65-81. PubMed ID: 11251246
[TBL] [Abstract][Full Text] [Related]
39. [Polysorbate-80 modified neurotoxin nanoparticle with its transport and cytotoxicity against blood-brain barrier].
Zhao YM; Xia AX; Wei YH; Ruan YP; Li FZ
Yao Xue Xue Bao; 2010 Oct; 45(10):1312-6. PubMed ID: 21348312
[TBL] [Abstract][Full Text] [Related]
40. Transport of Poly(n-butylcyano-acrylate) nanoparticles across the blood-brain barrier in vitro and their influence on barrier integrity.
Rempe R; Cramer S; Hüwel S; Galla HJ
Biochem Biophys Res Commun; 2011 Mar; 406(1):64-9. PubMed ID: 21295549
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
